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Epithelial-to-mesenchymal transition (EMT) is linked to tumor invasion, drug resistance and aggressive disease and
this is largely dependent on the cell's microenvironment. Acriflavine (ACF) is an old antibacterial drug recently also
suggested as anticancer agent and HIF inhibitor. We wanted to study the effect of acriflavine on EMT in different
human cancer models. Pancreatic cancer cells (Panc-1) were exposed to TGF-β1 or cobalt chloride (to mimick
severe hypoxia) to induce EMT. For our third model we exposed HepG2 liver cancer cells to sorafenib which
resulted in development of acquired drug resistance with strong features of EMT and aggressive behavior. These
models were morphologically and functionally (invasion assay) characterized. Markers of EMT were determined
using qRT-PCR and Western blotting. Transcriptome analysis was performed following gene expression
determination and combining the iRegulon tool and Gene Set Enrichment Analysis (GSEA). We made the
following observations: (1) acriflavine inhibited EMT based on changes in cell morphology, invasive capacities and
markers of EMT (at protein and gene expression level). (2) Transcriptome analysis revealed potent inhibition of
ATF4 target genes and of the unfolded protein response. We showed that acriflavine blocked eIF2a
phosphorylation and reduced ATF4 translation thereby inhibiting the PERK/eIF2a/ATF4 UPR pathway. (3) ACF
restored drug sensitivity of cells that obtained acquired resistance. Conclusions: We identified acriflavine as a
potent inhibitor of EMT and the UPR, thereby re-sensitizing the cancer cells to antineoplastic drugs.
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The effectiveness of systemic cancer therapy is limited by the inevitable
emergence of drug resistance. A diverse range of molecular mechanisms
are implicated in the reduced treatment responses [1]. EMT is a process in
which an epithelial cell, characterized by apical-basal polarity and
interaction with a basement membrane, undergoes a shift towards a more
motile, invasive state. For a long time, EMT was considered the driving
mechanism of the epithelial cancer cell to spread to distant organs and
formation of metastatic colonies. This paradigm was very recently
challenged by the finding that cells can metastasize also without
undergoing EMT [2,3]. In the same studies the important role of the
EMT program in drug resistance was confirmed.The (partial) activation of either the epithelial or the mesenchymal
program is largely dependent on the contextual signals that reach the
cell from its microenvironment (inflammation, hypoxia, metabolic
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macrophages and myofibroblasts, is the most studied inducer of the
mesenchymal phenotype [4–6].Hypoxia has also been reported to induce
EMT in cancer cells [7,8]. Furthermore, numerous studies have shown
that cell lines derived from various epithelial cancers undergo
mesenchymal differentiation in vitrowhenmade resistant to conventional
chemotherapy [9–11] as well as to targeted agents [12–14].
In response to stress such as nutrient deprivation, severe hypoxia or
pH changes, the tumor cell will also engage additional signaling
pathways such as the unfolded protein response (UPR) [15,16]). The
UPR is activated when the stressor disrupts normal protein folding in
the endoplasmic reticulum (ER) with the aim to ensure survival of the
cell. However, when cell stress is too severe and prolonged, the UPR
will facilitate apoptosis [15]. One of the main UPR signaling
pathways is driven by protein kinase RNA-like endoplasmic
reticulum kinase (PERK) activation, an ER transmembrane kinase,
which will lead to inhibition of Eukaryotic Initiation Factor 2a
(eIF2a) by phosphorylation hereby subsequently inducing the
Activating Transcription Factor 4 (ATF4) transcriptional program.
Deactivation of eIF2a will silence global mRNA translation to reduce
the ER protein load [17]. ATF4 is generally regarded as a pro-survival
regulator involved in drug resistance and its expression correlates with
EMT [18,19].
Acriflavine (ACF) is a heteroaromatic dye with antibacterial and
antiviral effects [20]. More recently, its potential as an anticancer
agent emerged as acriflavine has topo-isomerase inhibitor activity
[21]. It also blocks the HIF pathway, an important driver of cancer
aggressiveness, by preventing the dimerization of the HIF-1 subunits,
HIF-1α and HIF-1β [22]. Furthermore, there are also reports that
show a close link between HIF signaling, EMT and cancer
aggressiveness [7,8,23,24].
In this study, we show that acriflavine inhibits epithelial-
to-mesenchymal transition induced by TGF-β1 or CoCl2 (model of
severe hypoxia) and in a model of acquired drug resistance. Furthermore,
acriflavine blocks UPR via inhibition of the ATF4 transcriptional
program and resensitizes drug resistant cells. These characteristics
encourage further studies to repurpose ACF for systemic cancer therapy.
Methods
Cell Culture, EMT/UPR Induction and Acriflavine Treatment
Panc-1, human pancreatic cancer cells were obtained from ATCC
(CRL-1469, Rockville, MD, USA). EMT was induced by transform-
ing growth factor-β1 (TGF-β1, R&D systems, Minneapolis, USA) or
cobalt chloride (CoCl2) (Sigma-Aldrich, St. Louis, USA), the latter
compound to mimic severe hypoxia. Experimentally, cells were first
starved for 24 hours in medium with 1% fetal calf serum (FCS) to
avoid interference from growth factors in the serum and then
stimulated with TGF-β1 (5 ng/ml), CoCl2 (200 μM) or vehicle for
48 hours. The development of the sorafenib-resistant cell line
HepG2S1 (derived from human hepatoblastoma cell line HepG2
(ATCC, HB-8065) was done at the authors laboratory as described
previously [12]. HepG2S1 have strong mesenchymal characteristics
and are cultured continuously under drug selection with 6 μM of
sorafenib (Bayer HealthCare, Leverkusen, Germany). Gene expres-
sion of the different lines was repeatedly determined over time by
qRT-PCR and compared to transcriptome data of cells early after they
were obtained from ATCC, this to monitor stability. The
gemcitabine resistant human pancreatic cancer cell lines MiaPaCa-2GR800 and their parental cell line MiaPaca-2 were a kind gift of Prof.
T. Landowski [25] and were used to investigate the effect of ACF on
drug sensitivity by XTT cell viability assay as described below.
To inhibit EMT in Panc-1 cells, acriflavine (2.5 μM unless
otherwise specified) was added to the cell culture together with
TGF-β1 or CoCl2 for 48 h. As HepG2S1 cells show baseline EMT,
acriflavine or vehicle was added to unstimulated cells for 24 h. To
unravel the working mechanism of acriflavine, the compound was
also added to unstimulated Panc-1 cells, for further details see
Supplementary File.
Invasion Assay
Invasion studies were performed using BioCoat Matrigel Invasion
Chambers (Corning, NY, USA). Cells (7.5 x 104) were added to the
top inserts in FCS free medium with or without TGF-β1 (for Panc-1)
and/or 2.5 μM of ACF (for both Panc-1 and HepG2S1). The bottom
chambers were filled with medium containing 10% FCS, serving as a
chemo attractant. After 48 h, the non-invaded cells were removed
with a cotton swab and the assays were fixed and stained using
DiffQuick (Medion Diagnostics AG, Düdingen, Switzerland). The
number of invaded cells was determined under the microscope in five
random fields per insert at 40× magnification.
Western Blot
Ten to fiftymicrograms of protein per condition, obtained by cell lysis,
were separated on a Mini-PROTEAN® TGX™ precast gel (BioRad, CA,
USA). Proteins were transferred onto a nitrocellulose membrane and
subsequently incubated with the appropriate primary and secondary
antibodies (see Supplementary File). The immunoreactive bands were
visualized using the enhanced chemiluminescent Western blot detection
kit (BioRad). To verify equal protein loading, the blots were reprobed
with β-actin antibody (Sigma-Aldrich). Images were visualized using the
ChemiDoc™MP Imaging System (BioRad).
RNA Isolation and qRT-PCR
RNA from three biological cell culture controls was isolated with
the RNeasy Kit (Qiagen, Chatsworth, CA) according to the
manufacturer's instructions. One microgram of cellular RNA was
reverse transcribed into cDNA using SuperScript II reverse
transcriptase and random hexamer primers (Invitrogen/Life Tech-
nologies, USA). The PCR reaction was carried out in a mixture that
contained appropriate sense- and anti-sense primers and a TaqMan
MGB probe in Taq-Man Universal PCR Master Mixture (Applied
Biosystems, Foster City, CA, USA) (see Supplementary File).
Beta-2-microglobulin was used as housekeeping gene. qRT-PCR
amplification and data analysis were performed using the Lightcycler
96 (Roche Applied Science, Penzberg, Germany). Each sample was
assayed in duplicate. The ΔΔCq method was used to determine
relative gene expression levels.
cDNA Microarray and RNA Sequencing and Data Processing
To explore changes at the transcriptome level under experimental
conditions and to gain insights into the working mechanism of
acriflavine, cell culture samples were analyzed using cDNA
microarray (unstimulated Panc-1 cells and TGF-β1 experiment) or
RNA sequencing (HepG2S1 and CoCl2 experiment). Panc-1 cells
were treated with 2.5 μM of ACF for 48 h (with or without
concomitant stimulation). HepG2S1 cells were treated with 5 mM of
ACF for 24 h. RNA was extracted as described above. The RNA
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Alto, CA). All samples were analyzed in triplicate (biological controls).
For microarray, the Affymetrix Human PrimeView Array was used
as a platform. Gene expression data was analyzed with the Limma
package from Bioconductor (http://www.bioconductor.org) [26].
Differentially expressed genes were assessed using a moderated t test.
For RNA sequencing, poly-A containing mRNA molecules were
purified from the total RNA input using poly-T oligo-attached
magnetic beads. Samples were sequenced on an Illumina NextSeq
500 half-flow cell. After preprocessing, reads were aligned with STAR
2.4.1d to the reference genome of Homo sapiens (GRCh37.73) [27]
and counted with featureCounts 1.4.6 [28]. With the EdgeR 3.8.6
package of Bioconductor, generalized linear model (GLM) was fitted
against the normalized counts [29]. The resulting p-values of the
Limma and EdgeR packages were corrected for multiple testing with
Benjamini–Hochberg to control false discovery rate [30]. A gene was
considered differentially expressed if a 2log fold change N + 1 or b−1
and a corrected P b .05.
Microarray and RNA sequencing data are available at the Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under
accession number GSE82299.
The iRegulon tool identifies transcription factors regulating
differentially expressed genes based on binding motifs and ChIP-seq
data (tracks) [31]. We used this in silico analysis to predict the working
mechanism of acriflavine. The genes differentially expressed in one
direction upon stimulation and/or treatment were used as input. Only
the transcription factors with the highest enrichment score were further
evaluated. GSEA was performed of every experimental condition using
the entire MSig database [32]. Only gene sets with enrichment P value
b0.05 and FDR q-value b0.25 were considered significantly enriched
(see Supplementary File).
Cell Viability Assay
Cell viability and proliferation was measured with the “Cell
Proliferation Kit II (XTT)” (Roche). All experiments were performed
at least three times with every condition in triplicate. Culture
conditions were maintained in 96 well plates during 72 h (with
refreshment of medium and compounds after 48 h). XTT solution
was added to the wells at a concentration of 0.3 mg/mL and after 4 h
of incubation with XTT assay, the metabolic activity as an indirect
measure for cell number, was quantified spectrophotometrically at
dual wavelength (490–655 nm). Results were expressed relative to
control conditions.
Statistical Analysis
All statistics were performed using SPSS v23 (IBM). Statistical
differences between groups were assessed with a Student's t-test or the
Mann–Whitney Rank Sum Test when appropriate. For differences in
gene expression assessed by qRT-PCR, ANOVA test with post hoc
Tukey's procedure was used. A P value below .05 was considered
statistical significant.Results
Acriflavine Inhibits EMT
We investigated 3 mechanistically distinct models of EMT: (1)
Panc-1 cells stimulated with TGF-β1, (2) Panc-1 cells exposed to
chemically induced hypoxia (CoCl2) and (3) HepG2 cells resistant to
sorafenib (HepG2S1 cells). Light microscope confirmed loosening ofcell–cell contact and the acquisition of a spindle-shaped morphology
after stimulation of Panc-1 cells with TGF-β1 or CoCl2 (Figure 1, A
and B). On a functional level, stimulated Panc-1 cells acquired
enhanced invasive capacities when assessed by Matrigel invasion assay
(Figure 2A). Gene (qRT-PCR) and protein expression (Western blot)
of EMT markers showed down-regulation of CDH1, a hallmark of
EMT (Figure 3, A and B). These changes were accompanied by
up-regulation of the EMT transcription factor SNAI1. Similar
changes in EMT markers were seen in the CoCl2 model (data not
shown). Drug-resistant HepG2S1 cells underwent marked changes in
morphology, invasive capacity and gene and protein expression
compared to the parental HepG2 cells, compatible with pronounced
EMT (Figures 1C and 2B) (as described previously (12)). Gene
expression changes for the 3 models, as accessed by cDNA microarray
or RNA sequencing, confirmed EMT characteristics (see GEO data
GSE82299).
Next, we could demonstrate that acriflavine inhibits EMT. When
cells were stimulated with TGF-β1 or CoCl2 and simultaneously
treated with ACF, they partially regained their epithelial character-
istics, including closer cell–cell contact, this was most notably in the
Panc-1/TGF-β1 model (Figure 1A). In contrast, no major change in
morphology was noted in HepG2S1 cells treated with ACF alone
(Figure 1C) (see discussion). ACF strongly inhibited the invasive
potential of stimulated Panc-1 cells (Figure 2A) and HepG2S1 cells
(Figure 2B). qRT-PCR and Western blot confirmed up-regulation of
epithelial markers as well as down-regulation of mesenchymal markers
upon ACF treatment (Figure 3, A–C). On the transcriptome level,
acriflavine restored the expression of 191 of the 421 (45%)
differentially expressed genes after EMT-induction by TGF-β1
stimulation and 214 of 611 (35%) genes by CoCl2 stimulation
(Figure 3D).
Acriflavine Restores Drug Sensitivity
We investigated whether acriflavine could enhance the sensitivity
to cytotoxic drugs in the sorafenib-resistant HepG2S1 cells and
gemcitabine resistant MiaPaCa-2 cells GR800. The latter cell line
shows similar invasive characteristics and morphology as seen in
HepG2S1 cells although without the typical marker expression profile
of EMT [25]. In vitro, monotherapy with acriflavine at increased
dose, was cytotoxic for all cell lines tested. However, the IC50 of ACF
in the derived resistant cell lines; HepG2S1 and GR800 was higher
compared to their parental cell lines; HepG2 and MiaPaCa-2,
respectively (Figure 4). Treating resistant cells with an on itself
non-toxic concentration of ACF leads to a significant enhancement of
sorafenib sensitivity in HepG2S1 cells or that for gemcitabine in
GR800 cells (Figure 4). These findings confirmed that ACF restores
drug sensitivity in these models of mesenchymal differentiation upon
acquired drug resistance.
Acriflavine Inhibits UPR Via ATF4
It is clear from several reports that acriflavine can have an effect on
multiple cellular pathways [21,22]. To further unravel the mecha-
nism of action of ACF, we assessed the gene expression changes upon
ACF treatment in unstimulated Panc-1 cells (so without TGF-β1 or
CoCl2) and in HepG2S1 cells. Here, ACF led to remarkable
inhibition of the unfolded protein response, demonstrated by gene set
enrichment analysis (Figure 5A). The iRegulon tool pointed towards
either ATF4, ATF3 or CEBPB as potential involved transcription
factors of those genes down-regulated upon ACF treatment (Figure
Figure 1. Morphological changes in the different EMT models before and after treatment with ACF. Cells were cultured in their
appropriate medium. EMT was induced using TGF-β1 or CoCl2 after 24 hour pretreatment with medium of 1% FCS (for Panc-1 cells) or
after development of resistance against sorafenib (HepG2S1). Effect of ACF on morphology were observed under phase-contrast
microscope on cells co-treated with a non-lethal dose of 2.5 μMACF. The arrows indicate spindle shaped cells a morphological feature of
EMT. Scale bars represent 200 μm. (For details see materials and methods).
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UPR, we hypothesized that this transcription factor was indeed
inhibited by ACF and not those regulators with similar binding
motifs: ATF3 or CEBPB. Other arguments were derived from
comparisons of our data with that of other published research. We
found striking overlap between the genes down-regulated by
knockdown of ATF4 in a lung cancer cell line [33] and genes
down-regulated by ACF in the Panc-1 and HepG2S1 cell line (Figure
5A). Genes, down-regulated by ACF with an ATF4 binding motif in
their regulatory control elements, were partially common and
partially exclusive per cell type (Figure 5C). Gene sets containing
members with promotor regions around the transcription start site of
ATF3 or CEBPB were not significantly enriched or even significantly
up-regulated after ACF treatment in Panc-1 or HepG2S1 cells (data
not shown), suggesting that indeed ATF4 is most likely inhibited by
ACF leading to UPR abrogation.
Acriflavine Inhibits UPR by Dephosphorylation of eIF2a
When cell lines are cultured in normoxia they have low baseline ER
stress and limited unfolded protein response. We could confirm that
chemically induced severe hypoxia indeed activated the UPR, which
was inhibited by ACF (Figure 6A). ATF4 mRNA and protein levels
were significantly up-regulated upon CoCl2 stimulation and restored
to baseline by ACF (Figure 6, B and C). ATF4 targets weresignificantly induced by CoCl2 and inhibited by ACF (Figure 6A). Of
note, expression of carbonic anhydrase 9 (CA9), a known target of
ATF4 [34], was markedly induced by CoCl2 and restored to baseline
levels upon concomitant CoCl2 stimulation and ACF treatment
(Figure 6B). Low CA9 levels are associated with reduced tumor cell
survival in acidic as well as hypoxic environment [35]. CoCl2 also
causes an amino acid deprivation response with, among others,
up-regulation of tRNA synthetases. The expression of these ATF4
targets (a majority of the cytoplasmic forms and no mitochondrial
tRNA synthetases) was strongly repressed by acriflavine (Figure 6D)
(see also Supplementary File). More upstream of ATF4 in the PERK/
eIF2a/ATF4 pathway, Western blot confirmed inhibition of eIF2a
phosphorylation hereby tempering the unfolded protein response
(Figure 6C). In line with previous findings [19], we found that EMT
induction by TGF-β1 leads to activation of the PERK/eIF2a/ATF4
illustrated by phosphorylation of eIF2a and up-regulation of ATF4.
However, the ATF4 transcriptional program is not activated to an extent
comparable with CoCl2 stimulation as evaluated by iRegulon and GSEA
(data not shown).Nevertheless, ACF inhibits phosphorylation of eIF2a in
this model thereby reducing ATF4 levels (Figure 6C).
Discussion
With this study, we provided evidence that acriflavine can interfere
with EMT and UPR, two well-described pathways associated with
Figure 2. Invasive capacities of the EMT models before and after treatment with ACF. Invasion studies were performed as described in
materials and method section. After 48 hours the cells that had invaded were fixed, stained and counted. The results are the mean of 3
biological repeats +/− SD. On the right side representative pictures of the microscopic view of the matrigel are given. Original
magnification 10×, *: P b .001.
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associated with the mesenchymal state [36], blocking of the
epithelial-to-mesenchymal transition is an attractive goal in ACF
cancer therapy.
We could show that acriflavine, an old antibiotic recently identified
as anticancer agent and HIF inhibitor [22], efficiently inhibits EMT
in vitro. Expression of several important epithelial and mesenchymal
markers that were altered by EMT induction can be restored using
acriflavine (gene and protein level). At the morphological level, we
showed that induced Panc-1 cells (CoCl2 or TGF-β1: mesenchymal)
following acriflavine treatment regain closer cell–cell contact as is seen
in the non-stimulated Panc-1 cells (epithelial). In HepG2S1 cells, the
phenotype is much more pronounced and “fixed” probably due to
numerous genetic and epigenetic alterations present in these cells,
which was already shown in similar models of mesenchymal
differentiation upon acquired drug resistance [37]. Nevertheless,
the invasive capacities of stimulated Panc-1 cells and of HepG2S1
could be abrogated by a noncytotoxic concentration of acriflavine.
Much more than the expression of a single epithelial or mesenchymal
marker, this effect on the cellular behavior is crucial to demonstrate
EMT inhibitory activity.
Another remarkable effect of acriflavine is the inhibition of the
unfolded protein response. The role of the UPR is to limit cellular
damage during stress, explaining why the UPR has been linked to
cancer drug resistance [18]. However, this mechanism equally drivesthe cell to apoptosis when the stress is too severe [38]. Given this dual
role, the question rises whether either inhibition or stimulation of the
UPR for cancer therapy is most desirable. With this study, we showed
that acriflavine causes dephosphorylation of eIF2a, hereby inhibiting
the ATF4 transcriptional program. ATF4 is one of the central
transcription factors in the UPR induced by severe hypoxia or anoxia,
independent of HIF signaling [39]. ATF4 is generally regarded as a
pro-survival factor associated with resistance to anti-cancer drugs,
which makes it an attractive target [18]. Several approaches to target
ATF4 have been suggested, including the inhibition of upstream
factors PERK and eIF2a [40]. To the best of our knowledge, no drugs
have yet demonstrated to clearly abrogate the ATF4 transcriptional
program. Moreover, several genes regulated by ATF4 and affected by
ACF, such as carbonic anhydrase 9, are attractive targets for cancer
therapy [41]. Acriflavine can thus be considered as a broad hypoxia
pathway inhibitor in in vitro cancer models. Earlier, the drug was
identified as a HIF inhibitor by preventing dimerization of the two
HIF-1 subunits [22]. We now show that ACF also blocks the
alternative hypoxia pathway via ER stress causing abrogation of
hypoxic cell survival [42]. To be noted, ACF suppresses predomi-
nantly the expression of cytoplasmic aminoacyl t-RNA synthetases
and not the mitochondrial forms (see Supplementary Table 4)
suggesting that the mitochondria and energy supply of the cell are not
affected. Furthermore, in two models, hepatoma cells resistant to
sorafenib and pancreatic cancer cells resistant to gemcitabine, we
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line. Together, these action mechanisms of ACF result in diminished
invasion and resensitization of cancer cells in vitro.
Being an in vitro study it has some limitations before it can be
translated to the clinic. We investigated several cell models in which
the results on EMT or ACF are not always identical. We selected themodels to be complementary, we saw that EMT induction by
stimulation (TGF-β1 or CoCl2) is functional not very different from
the drug resistance models although certain molecular features are not
exactly the same. The same variation is to be expected when in vivo
different microenvironmental factors induce a cancer cells to EMT.
We then looked for features that could be repeated in the different
Figure 4. ACF partially restores drug sensitivity in models of acquired resistance. Dose dependent cell death was investigated using XTT
assay as described in materials and methods. A) Sensitivity of HepG2 and derived sorafenib-resistant HepG2S1 cells to ACF. B) ACF at a
non-lethal dose restores sorafenib sensitivity in HepG2S1 cells. C) Sensitivity of MiaPaCa-2 and derived gemcitabine resistant cell line
GR800 to ACF. D) Similarly, ACF restores gemcitabine sensitivity in GR800 cells.
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the linkage of transcriptome data with alterations in cellular programs
EMT and UPR. Although these findings are very suggestive for a
causal relationship, additional mechanistic studies are needed to
definitely confirm our hypotheses. However, recent studies have
shown that PERK/eIF2a activation is necessary for EMT cells to
invade and metastasize providing a link between the two concepts
[19]. Moreover, ATF4 knock-down impedes hypoxia induced EMT
in gastric cancer cell lines [16].
From these and other studies, it is clear that acriflavine is an
interesting compound with pleiotropic anticancer effects [21,22,43].
Its past systemic use in the clinical setting as an antibiotic without any
major toxicity reported encourages further development of the drug
for cancer treatment [44]. We hypothesize that ACF pushes the
cancer cell to an epithelial state, blocking the development of drug
resistance and prolonging the time frame over which a drug can haveFigure 3. Gene and protein expression analysis in models of EMT
determined in the Panc-1/TGF-β1 model. After 24 hours of growth i
without ACF the cells were harvested and qRT-PCR performed. (B
E-cadherin, Vimentin and Snai1. Representative blots are shown here
cells treated with different concentrations of ACF for 24 hours. (D) A
EMT models. We analyzed the genes that were differentially expres
co-treatment with ACF using transcriptome data. Upon TGF-β1 stim
change N+1 or b−1 and pcorrb 0.05). Of these, ACF restored 45% of d
found 611 genes to be differentially expressed, here ACF restored 35%
qRT-PCR results are given as mean fold change +/− SD. (*: P b .05its effect on the tumor and so increasing its effectiveness. However, at
present no preparation for clinical use is available and the interest of
the industry in off-patent drugs is limited [45]. We believe studies like
these should prompt non-profit institutions to take initiatives that
allow repurposing acriflavine for animal and clinical testing in
oncology.
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